Description
SUMO2/3 Antibody | V2257IHC-7ML | Gentaur US, UK & Europe Disrtribition
Family: Primary antibody
Formulation: Prediluted in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide; *For IHC use only*
Format: Purified
Clone: SM23/496
Host Animal: Mouse
Clonality: Monoclonal (mouse origin)
Species Reactivity: Human
Application: IHC-P
Buffer: N/A
Limitation: This SUMO2/3 antibody is available for research use only.
Purity: Protein G purified
Description: This antibody reacts with both SUMO2 and SUMO3. The small ubiquitin-related modifier (SUMO) proteins, which include SUMO1, 2 and 3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursors that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2 and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets for a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO1/2/3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO1 utilizes Ubc9 for conjugation to several targets, which include MDM2, p53, PML and RanGap1. SUMO2/3 contribute to a greater percentage of protein modification than does SUMO1 and they can form polymeric chains. In addition, SUMO3 regulates beta-Amyloid generation and may be critical in the onset or progression of Alzheimer's disease.
Immunogen: Recombinant human SUMO2 protein was used as the immunogen for this SUMO2/3 antibody.
Storage: Store the SUMO2/3 antibody at 2-8oC (with azide) or aliquot and store at -20 °C or colder (without azide).
